psychedelics – Page 2

Down the rabbit hole – the psychological and neural mechanisms of psychedelic compounds and their use in treating mental health and medical conditions

mycolabadmin

Psychedelic compounds like psilocybin and LSD are showing significant promise for treating various mental health conditions including depression, anxiety, and PTSD. These substances appear to work through multiple mechanisms, including inducing profound mystical experiences and increasing neuroplasticity in the brain. Research indicates that environmental and contextual factors significantly influence how effective these treatments are, and even virtual reality experiences mimicking psychedelic effects show therapeutic benefits. The field is moving toward responsible, evidence-based clinical applications of psychedelics in psychiatry.

Leveraging psychedelic neuroscience to boost human creativity using artificial intelligence

mycolabadmin

Psychedelic drugs like LSD and psilocybin enhance creativity by disrupting the brain’s Default Mode Network, allowing people to break free from rigid thinking patterns. This paper proposes that artificial intelligence systems could be designed to mimic these same cognitive effects—introducing novel information, making unexpected connections, and gradually expanding comfort with new ideas—thereby enhancing human creativity without drugs. By personalizing AI systems to each person’s personality type and gradually increasing novelty levels, these tools could make creative thinking accessible to people who might not naturally gravitate toward it.

Meditation, psychedelics, and brain connectivity: A randomized controlled resting-state fMRI study of N,N-dimethyltryptamine and harmine in a meditation retreat

mycolabadmin

Researchers studied how meditation combined with a psychedelic compound called DMT affects the brain. They scanned 40 experienced meditators before and after a 3-day retreat, with some receiving the psychedelic and others a placebo. While meditation alone reduced connections between different brain networks, the psychedelic enhanced certain connections, suggesting the two practices may complement each other in promoting mental health.

The Role of Psychedelics in the Treatment of Substance Use Disorders: An Overview of Systematic Reviews

mycolabadmin

This research review examines how psychedelic drugs like psilocybin and ketamine might help treat addiction. Studies show these substances could help people quit alcohol, drugs, and smoking by reducing cravings and promoting long-term abstinence. While results are promising, scientists caution that more rigorous research is needed before these treatments can be recommended for regular medical use, and they acknowledge real risks associated with these powerful drugs.

Behavioral Phenotyping and Metabolomic Comparison of Chemically Synthesized Psilocybin and Psychedelic Mushroom Extract in a Zebrafish Depression Model

mycolabadmin

Researchers compared chemically made psilocybin with whole mushroom extract in zebrafish to test for depression-like effects. Both treatments reversed depressive behaviors and produced similar changes in brain chemicals, though the mushroom extract showed more neurotransmitter precursors. This study demonstrates that zebrafish can be useful models for studying how psychedelics might help treat depression.

Psychotomimetic compensation versus sensitization

mycolabadmin

This paper proposes a new way to understand why drugs that can cause psychosis-like effects (such as psilocybin, LSD, and ketamine) can also help treat depression and anxiety. The authors suggest that these drugs trigger compensatory responses in the brain that temporarily help us cope with stress, similar to how a runner’s high feels good during exercise. However, if someone uses these drugs repeatedly or experiences chronic stress, they may become sensitized and more vulnerable to developing actual psychotic symptoms over time.

Meta-correlation of the effect of ketamine and psilocybin induced subjective effects on therapeutic outcome

mycolabadmin

This study examined whether the psychological experiences people have while taking ketamine or psilocybin—such as feeling disconnected or having spiritual insights—are actually responsible for their mental health improvements. Researchers analyzed 23 studies and found that these subjective experiences explain about 10% of ketamine’s benefits and 24% of psilocybin’s benefits. Psilocybin’s effects appear more connected to therapeutic outcomes than ketamine’s, and both drugs showed stronger connections between subjective effects and treatment success in substance use disorder compared to depression.

Biological markers of treatment response to serotonergic psychedelic therapies: a systematic review

mycolabadmin

This review examines how scientists can predict which patients will benefit most from psychedelic-assisted therapy for depression by measuring biological markers in the brain and blood. Researchers found that certain brain changes and protein levels—particularly involving the amygdala, specific brain regions, and inflammation markers—appear linked to treatment success. While the current studies are small, they suggest that measuring these biological markers could eventually help doctors personalize psychedelic treatments for depression.

Effect of psilocybin on marble burying in ICR mice: role of 5-HT1A receptors and implications for the treatment of obsessive-compulsive disorder

mycolabadmin

Researchers tested whether psilocybin mushrooms could help treat obsessive-compulsive disorder (OCD) using mice. They found that psilocybin reduced compulsive burying behavior in mice, similar to how approved OCD medications work. The study revealed that this anti-compulsive effect works through different brain mechanisms than previously thought, and that combining psilocybin with another drug called buspirone might block psychedelic effects while keeping therapeutic benefits.

Development of the Japanese version of the Challenging Experience Questionnaire

mycolabadmin

Researchers have translated an important measurement tool called the Challenging Experience Questionnaire into Japanese. This tool helps doctors and researchers measure difficult feelings like fear and anxiety that people sometimes experience when taking psilocybin mushrooms as part of therapy. Having this questionnaire available in Japanese is important because it allows Japanese patients and researchers to participate in psychedelic research and understand these experiences better.

Research Topic: psychedelics